Combination NTI drugs offer precise treatment for complex conditions but face major gaps in generic availability due to bioequivalence challenges. Patients risk therapeutic failure or toxicity when generics are substituted, with no FDA-approved fixed-dose NTI combinations currently on the U.S. market.